NHS England has advised that it intends to publish new detailed standard operating procedures for the Cancer Drugs Fund (CDF) by June 2016. These will include any further general details concerning the nature of managed access agreements associated with a drug\u2019s entry into the Fund.<\/p>
The Accelerated Access Review (AAR) is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for National Health Service patients to innovative and cost effective new medicines and the CDF. The AAR is looking at the capability of the National Institute for Health and Care Excellence, NHS England and the Department to support innovative pathways for the assessment, adoption and reimbursement of treatments.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "dateOfAnswer" : {"_value" : "2016-03-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL6571"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-03-14T15:27:18Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2016-03-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer Drugs Fund"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what criteria NHS England and NICE will apply when deciding on the commercial agreement to be put in place to provide treatment to patients under the conditional approval route in the new Cancer Drugs Fund.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3396", "label" : {"_value" : "Biography information for Lord Clement-Jones"} } , "tablingMemberPrinted" : [{"_value" : "Lord Clement-Jones"} ], "uin" : "HL6570"} , {"_about" : "http://data.parliament.uk/resources/456336", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/456336/answer", "answerText" : {"_value" : "
NHS England has advised that it intends to publish new detailed standard operating procedures for the Cancer Drugs Fund (CDF) by June 2016. These will include any further general details concerning the nature of managed access agreements associated with a drug\u2019s entry into the Fund.<\/p>
The Accelerated Access Review (AAR) is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for National Health Service patients to innovative and cost effective new medicines and the CDF. The AAR is looking at the capability of the National Institute for Health and Care Excellence, NHS England and the Department to support innovative pathways for the assessment, adoption and reimbursement of treatments.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "dateOfAnswer" : {"_value" : "2016-03-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL6570"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-03-14T15:27:18.093Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2016-03-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer Drugs Fund"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what types of commercial agreements NHS England and NICE will be required to consider as part of the conditional approval route in the new Cancer Drugs Fund.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3396", "label" : {"_value" : "Biography information for Lord Clement-Jones"} } , "tablingMemberPrinted" : [{"_value" : "Lord Clement-Jones"} ], "uin" : "HL6571"} , {"_about" : "http://data.parliament.uk/resources/456337", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/456337/answer", "answerText" : {"_value" : "
NHS England\u2019s Board agreed, on 25 February 2016, a way forward which will see the proposed new arrangements for the Cancer Drugs Fund (CDF) going live on 1 July 2016<\/p>
We expect NHS England and the National Institute for Health and Care Excellence (NICE) to work together to ensure that both organisations have the necessary capability and capacity to implement these proposals, including the introduction of a conditional approval route.<\/p>
<\/p>
The Accelerated Access Review (AAR) is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for NHS patients to innovative and cost effective new medicines and the CDF. The AAR is looking at the capability of NICE, NHS England and the Department to support innovative pathways for the assessment, adoption and reimbursement of treatments.<\/p>
<\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "dateOfAnswer" : {"_value" : "2016-03-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-03-14T15:16:31.343Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-03-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer Drugs Fund"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what assessment they have made of NHS England\u2019s and NICE\u2019s capabilities in relation to the commercial negotiations between them and pharmaceutical manufacturers in respect of the conditional approval route under the new Cancer Drugs Fund.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3396", "label" : {"_value" : "Biography information for Lord Clement-Jones"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Clement-Jones"}
], "uin" : "HL6572"}
, {"_about" : "http://data.parliament.uk/resources/456349", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/456349/answer", "answerText" : {"_value" : " NHS England and Monitor are working closely together to ensure that the payment system supports service developments in the vanguard sites (including those where integrated diabetes care is a focus) as well as monitoring local innovative approaches to supporting integrated care taken by some clinical commissioning groups (CCGs). This is to ensure that the payment system keeps abreast with the development of future service models and is not a barrier to the development of new models of care.<\/p> <\/p> During 2016/17, NHS England will look at the current incentives and funding arrangements for diabetes to see how greater alignment could be achieved between the financial incentives for primary and secondary care.<\/p> <\/p> Information on how much money the National Health Service invested in structured education for diabetes patients is not collected centrally.<\/p> <\/p> Under the Health and Social Care Act (2012), NHS England has a statutory duty to conduct an annual assessment of every CCG. Since April 2013, CCGs have been assessed twice, for the period 2013/14 and for 2014/15.<\/p> <\/p> For 2016/17, NHS England will introduce a new CCG Improvement and Assessment Framework (CCG IAF). This new framework will align with NHS England\u2019s mandate and planning process, with the aim of driving improvements in a number of key areas including the management and care of people with diabetes.<\/p> <\/p> <\/p> NHS England has been working with Diabetes UK on including diabetes indicators in the CCG IAF. The proposed diabetes indicators are:<\/p> <\/p> - the percentage of diabetes patients that have achieved all three of the National Institute for Heath and Care Excellence recommended treatment targets; and<\/p> - newly diagnosed diabetes patients referred to, or attending, a structured education course.<\/p> <\/p> Under the proposals, diabetes will also be one of the six clinical priority areas in the CCG IAF that will be overseen by an independent group.<\/p> <\/p> The CCG IAF proposals are subject to the outcome of an engagement process which closed for comments on February 26 2016. More information can be found at:<\/p> <\/p> https://www.england.nhs.uk/commissioning/ccg-improvmnt/<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "dateOfAnswer" : {"_value" : "2016-03-14", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "HL6585"}
, {"_value" : "HL6586"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-03-14T15:15:42.943Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-03-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Diabetes"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what work NHS England and Monitor are undertaking to develop new payment and incentives mechanisms that drive integrated care for diabetes across primary and secondary care settings; and what is the time frame for any new proposals to be published.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/2488", "label" : {"_value" : "Biography information for Lord Harrison"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Harrison"}
], "uin" : "HL6583"}
, {"_about" : "http://data.parliament.uk/resources/456350", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/456350/answer", "answerText" : {"_value" : " The Health and Social Care Information Centre provides information on the number of nursing, midwifery and health visiting staff employed in the National Health Service in England but it does not separately identify diabetes specialist nurses.<\/p> <\/p> It is for local NHS organisations with their knowledge of the healthcare needs of their local population to invest in training for specialist skills and to deploy specialist nurses.<\/p> <\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "dateOfAnswer" : {"_value" : "2016-03-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-03-14T15:28:25.313Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-03-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Diabetes: Nurses"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government how many diabetes specialist nurses are currently employed by (1) each Clinical Commissioning Group area, and (2) each hospital trust, in England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/2488", "label" : {"_value" : "Biography information for Lord Harrison"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Harrison"}
], "uin" : "HL6584"}
, {"_about" : "http://data.parliament.uk/resources/456351", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/456351/answer", "answerText" : {"_value" : " NHS England and Monitor are working closely together to ensure that the payment system supports service developments in the vanguard sites (including those where integrated diabetes care is a focus) as well as monitoring local innovative approaches to supporting integrated care taken by some clinical commissioning groups (CCGs). This is to ensure that the payment system keeps abreast with the development of future service models and is not a barrier to the development of new models of care.<\/p> <\/p> During 2016/17, NHS England will look at the current incentives and funding arrangements for diabetes to see how greater alignment could be achieved between the financial incentives for primary and secondary care.<\/p> <\/p> Information on how much money the National Health Service invested in structured education for diabetes patients is not collected centrally.<\/p> <\/p> Under the Health and Social Care Act (2012), NHS England has a statutory duty to conduct an annual assessment of every CCG. Since April 2013, CCGs have been assessed twice, for the period 2013/14 and for 2014/15.<\/p> <\/p> For 2016/17, NHS England will introduce a new CCG Improvement and Assessment Framework (CCG IAF). This new framework will align with NHS England\u2019s mandate and planning process, with the aim of driving improvements in a number of key areas including the management and care of people with diabetes.<\/p> <\/p> <\/p> NHS England has been working with Diabetes UK on including diabetes indicators in the CCG IAF. The proposed diabetes indicators are:<\/p> <\/p> - the percentage of diabetes patients that have achieved all three of the National Institute for Heath and Care Excellence recommended treatment targets; and<\/p> - newly diagnosed diabetes patients referred to, or attending, a structured education course.<\/p> <\/p> Under the proposals, diabetes will also be one of the six clinical priority areas in the CCG IAF that will be overseen by an independent group.<\/p> <\/p> The CCG IAF proposals are subject to the outcome of an engagement process which closed for comments on February 26 2016. More information can be found at:<\/p> <\/p>